Head-to-Head trial tests best Second-Line treatment for low platelet disorder
NCT ID NCT07051915
Summary
This study aims to find out which of two common second-line treatments works better for adults with immune thrombocytopenia (ITP), a condition that causes low platelet counts and bleeding risk. About 220 participants will be randomly assigned to receive either a daily pill (avatrombopag) or an infusion treatment (rituximab) and followed for over a year. Researchers will compare how well each treatment raises and maintains platelet counts and improves patients' quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOCYTOPENIA PURPURA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.